What makes this result even more compelling is the fact that when we look individually at the datasets with known NPM1 mutants and stratify patients based on ALDH1A1 or ALDH2 expression, we note that the difference between NPM1 wild-type and mutant AML generally holds true. This evidence concerns the gene ALDH2 and acute myeloid leukemia.